| Dr Michael Perry Brook, MD | |
|
407 14th Ave Se, Puyallup, WA 98372-3770 | |
| (253) 697-1848 | |
| (253) 770-5990 |
| Full Name | Dr Michael Perry Brook |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 407 14th Ave Se, Puyallup, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295762060 | NPI | - | NPPES |
| 8116923 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD00027057 (Washington) | Primary |
| Entity Name | Mt. Rainier Emergency Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538104476 PECOS PAC ID: 7810980968 Enrollment ID: O20040406000189 |
News Archive
"Developing a Center for Comparative Effectiveness Information," Health Affairs: In a Health Affairs Web exclusive, Gail Wilensky - an economist, senior fellow at Project HOPE and former administrator of the Health Care Financing Administration - examines the growing interest in the U.S. for unbiased, credible information on comparative clinical effectiveness by those who support competitive health care pricing and by those who support administered pricing.
The importance of friendships and family support in helping prevent depression among teenagers has been highlighted in research from the University of Cambridge.
Roche announced today that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays. Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to QIAGEN's wholly owned subsidiary DxS, now QIAGEN Manchester.
A population-based case-control study found no association between bra wearing and increased breast cancer risk among postmenopausal women, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.
› Verified 1 days ago
| Entity Name | Western Washington Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801352505 PECOS PAC ID: 0749514735 Enrollment ID: O20190625002379 |
News Archive
"Developing a Center for Comparative Effectiveness Information," Health Affairs: In a Health Affairs Web exclusive, Gail Wilensky - an economist, senior fellow at Project HOPE and former administrator of the Health Care Financing Administration - examines the growing interest in the U.S. for unbiased, credible information on comparative clinical effectiveness by those who support competitive health care pricing and by those who support administered pricing.
The importance of friendships and family support in helping prevent depression among teenagers has been highlighted in research from the University of Cambridge.
Roche announced today that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays. Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to QIAGEN's wholly owned subsidiary DxS, now QIAGEN Manchester.
A population-based case-control study found no association between bra wearing and increased breast cancer risk among postmenopausal women, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Perry Brook, MD Po Box 662050, Arcadia, CA 91066-2050 Ph: (626) 447-0296 | Dr Michael Perry Brook, MD 407 14th Ave Se, Puyallup, WA 98372-3770 Ph: (253) 697-1848 |
News Archive
"Developing a Center for Comparative Effectiveness Information," Health Affairs: In a Health Affairs Web exclusive, Gail Wilensky - an economist, senior fellow at Project HOPE and former administrator of the Health Care Financing Administration - examines the growing interest in the U.S. for unbiased, credible information on comparative clinical effectiveness by those who support competitive health care pricing and by those who support administered pricing.
The importance of friendships and family support in helping prevent depression among teenagers has been highlighted in research from the University of Cambridge.
Roche announced today that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays. Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to QIAGEN's wholly owned subsidiary DxS, now QIAGEN Manchester.
A population-based case-control study found no association between bra wearing and increased breast cancer risk among postmenopausal women, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.
› Verified 1 days ago
Paul M Billing, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1706 Meridian S, Suite 120, Puyallup, WA 98371 Phone: 253-848-8797 Fax: 253-446-3239 | |
Dr. Eric B Tulley, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 407 14th Ave Se, Puyallup, WA 98372 Phone: 253-848-6661 Fax: 253-770-5990 | |
Dr. Bobbi A Sipes, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 407 14th Ave Se, 407-14th Ave. Se, Pob 1247, Puyallup, WA 98372 Phone: 253-697-1848 | |
Stephen Edmund Friedrick, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 15th Ave Se, Puyallup, WA 98372 Phone: 253-697-4000 | |
Dr. Michael John Regalado, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 407 14th Ave Se, Puyallup, WA 98372 Phone: 253-848-6661 Fax: 253-770-5990 | |
Dr. Ted Coleman, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 11102 Sunrise Blvd E, Suite 103, Puyallup, WA 98374 Phone: 253-848-8797 Fax: 253-845-0100 |